HGFR/c-MET, His & Avi, Human
HGFR/c-MET, His & Avi, Human

Immobilized Human c-MET, His & Avi Tag at 2 μg/ml (100 μl/Well). Dose response curve for Human HGF, hFc Tag with the EC50 of 0.16 μg/ml determined by ELISA.

HGFR/c-MET, His & Avi, Human

Human HGFR/c-MET on SDS-PAGE under reducing conditions. The purity is greater than 95%.

HGFR/c-MET, His & Avi, Human

The purity of Human HGFR/c-MET is greater than 95% as determined by SEC-HPLC.

HGFR/c-MET, His & Avi, Human

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling.
Z03634
¥36,250.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HGFR/c-MET (Glu25-Thr932)
Accession # P08581
Poly-His Avi
N-term C-term
Purity > 95% as analyzed by SDS-PAGE
> 95% as analyzed by HPLC
Endotoxin Level ≤ 1 EU/μg of protein by LAL method
Biological Activity Immobilized Human c-MET, His & Avi Tag at 2.0 μg/ml (100 μl/Well). Dose response curve for Human HGF, hFc Tag with the EC50 of 0.16 μg/ml determined by ELISA.
Expression System Expi293
Apparent Molecular Weight 80~85 kDa, on SDS-PAGE under reducing conditions.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. Normally 5 % trehalose is added as protectant before lyophilization.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in distilled water up to 100 μg/ml.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Avoid repeated freeze-thaw cycles.

Examples
  • HGFR/c-MET, His & Avi, Human
  • HGFR/c-MET, His & Avi, Human

    Immobilized Human c-MET, His & Avi Tag at 2 μg/ml (100 μl/Well). Dose response curve for Human HGF, hFc Tag with the EC50 of 0.16 μg/ml determined by ELISA.

  • HGFR/c-MET, His & Avi, Human
  • HGFR/c-MET, His & Avi, Human

    Human HGFR/c-MET on SDS-PAGE under reducing conditions. The purity is greater than 95%.

  • HGFR/c-MET, His & Avi, Human
  • HGFR/c-MET, His & Avi, Human

    The purity of Human HGFR/c-MET is greater than 95% as determined by SEC-HPLC.


Background
Target Background c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. The RAS-ERK activation is associated with the morphogenetic effects while PI3K/AKT coordinates prosurvival effects. During embryonic development, MET signaling.
Synonyms MET; oncogene MET; Proto-oncogene c-Met; HGF R; HGF receptor; HGF/SF receptor; HGFR; AUTS9; cMET; c-MET; EC 2.7.10; EC 2.7.10.1; hepatocyte growth factor receptor; Met (c-Met); met proto-oncogene (hepatocyte growth factor receptor); met proto-oncogene tyrosine kinase; RCCP2; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.